



Vaccinations For Paediatric Patients Treated With Standard-Dose Chemotherapy And Haemopoietic Stem Cell Transplantation (HSCT) Recipients

Authors: Dr Soonie R.Patel, Professor Rod Skinner and Professor Paul T.Heath

Date: July 2018

Review date: July 2020

The CCLG does not sponsor nor indemnify the treatment detailed herein. These clinical guidelines are provided by the CCLG Germ Cell Tumour Special Interest Group to inform and for use at the sole discretion of treating clinicians who retain professional responsibility for their actions and treatment decisions. Treatment recommendations are based on current best practice and not what is necessarily proposed for any forthcoming clinical trial.

Table of Contents

1. INTRODUCTION: VACCINATIONS FOR PAEDIATRIC PATIENTS TREATED WITH STANDARD-DOSE CHEMOTHERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION (HSCT) RECIPIENTS	3
2. VACCINATIONS FOR PAEDIATRIC PATIENTS TREATED WITH STANDARD-DOSE CHEMOTHERAPY	4
2.1 Background	4
2.2 General Principles	5
2.3 Vaccinations for patients receiving standard-dose chemotherapy (or within 6 months of completion)	5
2.4 Vaccination schedule for patients beginning 6 months after completion of standard-dose Chemotherapy	5
2.5 Vaccination of close contacts of patients receiving standard-dose chemotherapy (or within 6 months of completion)	7
3. VACCINATIONS IN CHILDREN TREATED WITH HIGH DOSE CHEMOTHERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION (HSCT)	8
3.1 Background	8
3.2 General Principles	9
3.3 Re-vaccination Schedule for HSCT Recipients	10
3.4 Other Vaccines	11
3.5 Vaccines contraindicated for HSCT Recipients	11
3.6 Vaccination of close contacts of HSCT Recipients	11
REFERENCES:	13
APPENDIX 1	14
APPENDIX 2	15

1. INTRODUCTION: VACCINATIONS FOR PAEDIATRIC PATIENTS TREATED WITH STANDARD-DOSE CHEMOTHERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION (HSCT) RECIPIENTS

Most children with cancer are immunocompromised. The cancer itself may cause a variable degree of immunosuppression but it is the cytotoxic anti-cancer therapy that is the main contributor. The majority of children with cancer are treated with standard-dose chemotherapy but some children require high dose chemotherapy +/- radiotherapy followed by haematopoietic stem cell transplant (HSCT). These different forms of treatment have different influences on the immune system and the degree of immunodeficiency. Immune alteration is reflected by decreases in neutrophils, lymphocytes, immunoglobulin levels and specific antibodies against previous vaccinations.

Most of the vaccine-preventable diseases are now fortunately rare. However, the risk for some remains significant, in part due to increases in migration and travel. Furthermore they can be associated with high morbidity and mortality, particularly in immunocompromised patients. In view of the secondary immunodeficiency of children treated for cancer, particularly HSCT recipients, and their improved long-term survival after completion of treatment, it is important to ensure that they are protected against vaccine-preventable diseases. This can be achieved by optimising the vaccination strategy in children during chemotherapy and by re-vaccination of children after completion of chemotherapy. In view of the diversity of malignant diseases and their treatment protocols, it would be difficult to propose different vaccination schedules for each disease. Rather it is sensible to divide into children treated with standard-dose chemotherapy and children treated with high-dose chemotherapy (+/- radiation) followed by allogeneic or autologous HSCT.

2. VACCINATIONS FOR PAEDIATRIC PATIENTS TREATED WITH STANDARD-DOSE CHEMOTHERAPY

2.1 Background

Different cancers require treatment with different combinations of chemotherapy agents. Therapy for a single disease is risk-stratified based on patient factors, extent of disease and tumour biology, so there may be variation in intensity of therapy for a single disease type. Therapy regimens that include agents such as cyclophosphamide, purine nucleoside analogues or corticosteroids are immunosuppressive; they particularly have an effect on lymphocyte function. Some treatment regimens include radiation therapy; there are few data on the influence of radiotherapy on immunosuppression. If radiation therapy involves the spleen functional hyposplenia or asplenia can result which increases susceptibility to infection with polysaccharide encapsulated bacteria.

Depending on the treatment regimen, B- and T-lymphocyte levels decrease during treatment; with an increase in number occurring one month after completion of chemotherapy. Total B- and T-lymphocytes usually recover fully quantitatively and functionally six months after completion of chemotherapy, although in some cases recovery may take up to one year.

There are published studies demonstrating a reduction in immunity to vaccine antigens such as *Haemophilus influenzae* type b (Hib), Meningococcus C (Men C), tetanus, polio, measles and pneumococcus serotypes; and protective antibody responses have been demonstrated to these antigens with a vaccination regimen beginning 6 months after completion of treatment. However, there are no published data in this group of patients on immunity to, or immune response to, newer vaccines such as Human Papilloma Virus vaccine (HPV).

Clinical experience suggests that there is an increased risk for meningococcal infection in children who have been treated for cancer and therefore we have recommended booster vaccine doses for Men B and Men C, and expedite vaccination for Men ACWY rather than waiting until age 14 years per the national schedule.

There is a reduction in vaccine-antigen specific antibody concentrations after completion of chemotherapy. It is therefore wise to follow the same vaccination recommendations for all patients treated with standard-dose chemotherapy.

2.2 General Principles

- Avoid administration of all live vaccines to patients on chemotherapy and within 6 months following completion of chemotherapy.
- Avoid administration of live vaccines, except Measles/Mumps/Rubella (MMR), Varicella Zoster Virus (VZV), Live attenuated Influenza vaccine (LAIV) and Rotavirus vaccines, to siblings of patients on chemotherapy (or within 6 months following completion of chemotherapy).
- VZV vaccine should be offered to healthy susceptible siblings and other family members of patients receiving chemotherapy.
- Inactivated Influenza vaccine should be offered to all patients receiving chemotherapy or are within 6 months of completion of chemotherapy.
- Influenza vaccine should be advised for close contacts
- Update primary health care records if vaccination takes place in hospital

2.3 Vaccinations for patients receiving standard-dose chemotherapy (or within 6 months of completion)

Consider following the timing and content of the routine childhood vaccination programme, using only non-live vaccines provided the child's general condition is stable and is expected to stay so for 3 weeks from vaccination.

Avoid vaccination during the period that the patient is receiving steroids (the immune response will be suboptimal) or the patient is neutropenic (neutrophil count <0.5).

Inactivated influenza vaccine is recommended annually in the autumn for all patients on chemotherapy or within 6 months of its completion. The live attenuated intranasal vaccine should not be given to this group of patients. Influenza vaccine should be given to family members during treatment and within six months of completion of treatment.

2.4 Vaccination schedule for patients beginning 6 months after completion of standard-dose Chemotherapy

Six months after completion of standard dose chemotherapy a booster dose of vaccinations should be given. This is detailed in the table below.

If the child did not complete the course of childhood vaccinations prior to starting treatment then this should be completed.

Booster vaccination schedule 6 months after completion of Standard dose Chemotherapy

Time after EOT	Age under 10 years Vaccine	Age 10 years and over Vaccine
6 Months	DTaP / IPV ^{1,2} (Infanrix-IPV) Hib/Men C ^{1,2} (Menitorix) DTaP/IPV/Hib/HepB ² (Infanrix hexa) Men ACWY-conjugate (Menveo) PCV13 (Prevenar 13) Men B ³ (Bexsero) MMR ⁴ (Priorix or MMRVaxPRO)	dTaP / IPV ¹ (Repevax) Hib/Men C (Menitorix) Men ACWY-conjugate (Menveo) PCV13 (Prevenar 13) Men B ³ (Bexsero) MMR ⁴ (Priorix or MMRVaxPRO) HPV ⁵ (Gardasil)

[Vaccines: DTaP = Diphtheria/ Tetanus/ acellular Pertussis, dTaP = Low dose Diphtheria/ Tetanus/ acellular Pertussis, Hib = *H.influenzae b* conjugate, HepB =Hepatitis B, HPV = Human papillomavirus, IPV = Inactivated polio virus vaccine, Men B = Meningococcal B conjugate, Men C = Meningococcal C conjugate, Men ACWY = Meninococcal ACWY conjugate, MMR = Measles/Mumps/Rubella, PCV13 = 13 valent Pneumococcal conjugate, PnPS 23 = 23 valent pneumococcal polysaccharide]

¹ Can be given Infanrix-IPV (for <10 years age) or Repevax (for ≥10 years age)

² Give DTaP/IPV/Hib/HepB (Infanrix hexa) to children born after 1/07/17. Otherwise give DTaP / IPV (Infanrix-IPV) and Hib/Men C (Menitorix)

³ Give Men B vaccine to children born after 1/09/15

⁴ If patient did not receive MMR prior to starting chemotherapy give 2 doses MMR, if patient only received 1 dose of MMR prior to starting chemotherapy then should receive 2 doses of MMR after completion of chemotherapy. The 2nd dose should be given 6 months after the 1st dose. The 2nd dose can be given 3 months after the 1st dose or can be considered even earlier (1 month after 1st dose) in measles outbreak.

⁵ HPV vaccine should be offered to girls ≥12 years old: 2 doses of HPV vaccine (Gardasil) should be given at 0 and 6 months from starting re-vaccination. If patient is aged 15 years and over, 3 doses recommended at 0, 1, 6 months from starting re-vaccination. For girls that did complete the course, a booster dose should be given.

Subsequent routine booster doses will not be necessary if scheduled to be given within one year of the above booster doses.

If patient has not received full vaccination schedule prior to diagnosis and treatment then complete the schedule.

BCG Vaccine: If patient has previously had BCG and is considered to be at high risk of tuberculosis, perform mantoux test and if negative, re-vaccinate. If patient has not previously had BCG then vaccinate according to local policy.

2.5 Vaccination of close contacts of patients receiving standard-dose chemotherapy (or within 6 months of completion)

The following live vaccines can be administered to siblings/ close family contacts of patients on chemotherapy or within 6 months following completion of chemotherapy.

- MMR Vaccine should be given to contacts as per the national vaccination schedule.
- VZV vaccine (Varivax®) should be offered to healthy susceptible siblings (and adult family members who are VZV seronegative) of VZV seronegative patients. There is theoretical risk of transmitting the attenuated vaccine virus to a susceptible individual; as a precautionary measure, any person who develops a vesicular rash after receiving VZV vaccine should avoid direct contact with the patient until the rash is dry and crusted.
- Shingles vaccine (Zostavax®): Is offered to adults aged 70-79 years old, so the patient's grandparents may be offered this vaccine. Rarely the transmission of vaccine virus may occur between those vaccinated who develop a varicella-like rash and susceptible contacts. As a precautionary measure, any person who develops a vesicular rash after receiving Zostavax® should avoid direct contact with the patient until the rash is dry and crusted.
- Rotavirus vaccine (Rotarix®): Is given to infants aged 6-24 weeks. Rotarix should not be given to the patient but can be given to siblings. There is potential for transmission from the infant to immunocompromised contacts through the faecal-oral route for at least 14 days post-vaccination. However, vaccination of the infant will offer protection to household contacts from wild-type rotavirus disease and outweigh any risk from transmission of vaccine virus to any immunocompromised close contacts. Good personal hygiene should be observed following administration of Rotarix.
- Live attenuated influenza vaccine (LAIV): Consideration should also be given to giving LAIV to household contacts that are eligible for LAIV; other household contacts should be given the inactivated Influenza vaccine. Siblings that are due should be given this; there is a theoretical potential for transmission of live attenuated influenza virus from LAIV to immunocompromised contacts for one to two weeks following vaccination so assess each individual case.

Travel Abroad

Live vaccines such as BCG, VZV, MMR, oral typhoid and yellow fever should be avoided during chemotherapy and for 6 months after completion of chemotherapy.

3. VACCINATIONS IN CHILDREN TREATED WITH HIGH DOSE CHEMOTHERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION (HSCT)

3.1 Background

HSCT recipients are profoundly immunosuppressed for several months, even years after transplantation. Immune reconstitution after HSCT occurs in a well-defined manner. The various components of the new immune system develop and mature at different rates and this dictates the timing and type of specific infections as well as the response to different antigens.

Immune reconstitution after autologous HSCT occurs faster than allogeneic HSCT. Innate immune function recovers earlier than adaptive immune function. A prolonged immune deficiency arises from a deficiency of the more specialised functions of the adaptive immune system, in particular, the reconstitution of CD4⁺-lymphocytes. B-lymphocyte numbers can recover three-months after transplant in recipients without chronic-GvHD, full functional recovery takes longer. Immunoglobulin levels start normalising six-months after transplant; IgG2 subclass is the last to recover. T-lymphocyte recovery is via thymic-independent and thymic-dependent pathways; recovery of naïve CD4⁺ T-lymphocytes is particularly slow.

Immunity to vaccine preventable diseases declines after HSCT; there are published reports showing a significant proportion of HSCT recipients to be susceptible to pathogens against which they had been successfully immunised prior to transplantation. There are few published reports on the incidence of vaccine-preventable diseases in HSCT recipients; the available reports show an increased incidence and/or morbidity and mortality for pneumococcal disease, varicella, measles and influenza. By the nature of immunosuppression present after HSCT it would be expected that HSCT recipients have a particularly increased risk of infections with polysaccharide-encapsulated bacteria. There are published studies demonstrating an increased incidence of pneumococcal disease.

A number of factors have an influence on immunity to vaccine antigens, and immunogenicity of vaccines in HSCT recipients; type of transplant, time lapse after transplant, chronic-GvHD, recipient age, the number of vaccine doses, and the actual vaccine.

It is not only of importance to the HSCT recipient to be protected against vaccine preventable diseases, particularly with increases in migration and travel, but also to maintain herd immunity. Therefore re-vaccination of HSCT recipients is indicated. There are few studies in this area on which to base vaccination recommendations and guidelines are therefore often based on expert opinion, and a limited number of published studies. This was the basis of the Royal College of Paediatrics and Child Health (RCPCH) guidelines, published in 2002. Since the publication of the RCPCH guideline further vaccine studies in HSCT recipients have been published.

The aim in HSCT recipients is to commence re-vaccination as soon as it is safe and as soon as a protective immune response can be achieved. Potentially this would be once the patient is off immunosuppressive therapy. In most published studies, however, vaccination schedules have been started ≥ 12 months after HSCT.

- All children should be considered for re-vaccination after allogeneic or autologous HSCT.
- In comparison to recipients of allogeneic HSCT, autologous HSCT recipients are less immune suppressed. However, both transplant types follow the same vaccination schedule content.
- The use of live vaccines is potentially dangerous until the child has been off all immunosuppressive treatment for at least 12 months and has no evidence of active chronic GvHD.
- Chronic GvHD and its treatment cause immune suppression, therefore these patients are at high risk of infectious complications.
- In view of the difficulty in predicting the extent of immune suppression and immune recovery, a pragmatic approach is to recommend re-vaccination of all recipients of allogeneic and autologous HSCT:

3.2 General Principles

Re-Vaccination should commence:

- 12 months after any HSCT (transplant team can review this on case by case basis - Normal serum immunoglobulins, CD4 count $>15\%$ and / or $>300 \times 10^6/L$)

Providing that:

- No evidence of active chronic GVHD
- Off all immunosuppressive treatment for at least 6 months, and for at least 12 months for live vaccines
- Off IVIg for at least 3 months

NB. In infants who have undergone allogeneic HSCT for primary immunodeficiency it may be appropriate to start vaccination earlier than specified above.

3.3 Re-vaccination Schedule for HSCT Recipients

Time after HSCT	Age under 10 years Vaccine	Age 10 years and over Vaccine
Every autumn (start 6 months after transplant)	Inactivated influenza ¹	Inactivated influenza ¹
12 Months	DTaP / IPV ^{2,3} (Infanrix-IPV) Hib / Men C ^{2,3} (Menitorix) DTaP/IPV/Hib/HepB ³ (Infanrix hexa) PCV13 Men B (Bexsero)	dTaP / IPV ² (Repevax) Hib / Men C ² (Menitorix) PCV13 Men B (Bexsero) HPV ⁴
13 Months	DTaP / IPV / Hib ^{2,3} (Pediacef) DTaP/IPV/Hib/HepB ³ (Infanrix hexa)	dTaP / IPV ² (Repevax) HPV ⁴
14 Months	DTaP / IPV ^{2,3} (Infanrix-IPV) Hib / Men C ^{2,3} DTaP/IPV/Hib/HepB ³ (Infanrix hexa) PCV13 Men B	dTaP / IPV ² (Repevax) Hib / Men C PCV13 Men B
18 Months	MMR ⁵	MMR ⁵ HPV ⁴
24 Months	MMR ⁵ Men ACWY Men B PCV13 or PnPS23	MMR ⁵ Men ACWY Men B PCV13 or PnPS23
48 Months	DTaP / IPV (Infanrix-IPV) Hib / Men C	dTaP / IPV (Repevax) Hib / Men C
School leaver booster	dT / IPV (Revaxis) Men ACWY	dT / IPV (Revaxis) Men ACWY

[Vaccines: DTaP = Diphtheria/ Tetanus/ acellular Pertussis, dTaP = Low dose Diphtheria/ Tetanus/ acellular Pertussis, Hib = *H.influenzae b* conjugate, HepB =Hepatitis B, HPV = Human papillomavirus, IPV = Inactivated polio virus vaccine, Men B = Meningococcal B conjugate, Men C = Meningococcal C conjugate, Men ACWY = Meningococcal ACWY conjugate, MMR = Measles/Mumps/Rubella, PCV13 = 13 valent Pneumococcal conjugate, PnPS 23 = 23 valent pneumococcal polysaccharide]

¹The intranasal live-attenuated influenza vaccine should not be given to HSCT recipients. Note that the immune response to influenza vaccine is not optimal during the first 6 months after HSCT, which is the period of greatest risk; therefore vaccination should be offered to family members and hospital staff.

² Can be given as Infanrix-IPV (for <10 years age at administration) or Repevax (for ≥10 years age)

³ Give DTaP/IPV/Hib/HepB (Infanrix hexa) to children born after 1/07/17. Otherwise give DTaP / IPV (Infanrix-IPV) and Hib/Men C (Menitorix). Can give DTaP/IPV/Hib/HepB if parents would prefer child to be immunised against Hepatitis B

⁴ HPV vaccine should be offered to girls ≥12 years old: 2 doses of HPV vaccine (Gardasil) should be given at 0 and 6 months from starting re-vaccination. If patient is aged 15 years and over, 3 doses recommended at 0,1, 6 months from starting re-vaccination.

⁵ 1st dose of MMR should be given at 18 months provided patient is at least 12 months off all immunosuppressive treatment and fulfils criteria

⁵ The 2nd dose of MMR is usually given 6 months after the 1st dose, but can be given 3 months after the 1st or even earlier (1 month after 1st dose) in outbreak situations.

3.4 Other Vaccines

Hepatitis B vaccine, travel vaccines and BCG vaccine may be considered for individual cases (after discussion with the transplant team).

There is little data about the safety and effectiveness of the BCG vaccine in HSCT recipients. Its use is not recommended unless there is a clear case of need such as travel to or residence in an area with a high incidence of tuberculosis (greater than 40/ 100,000 per year), and provided the patient has no active chronic-GvHD and there is evidence of immune function recovery (such as normal serum immunoglobulin concentrations, recovery of lymphocyte function and CD4-lymphocyte numbers). Prior to administering BCG, particularly in patients that have previously had BCG, a tuberculin skin test should be done.

3.5 Vaccines contraindicated for HSCT Recipients

- BCG (except in specific circumstances – see section 3.4 and only after discussion with transplant or immunology team)
- Rotavirus
- Intranasal live attenuated Influenza vaccine
- VZV vaccine
- Yellow fever
- Live attenuated Typhoid vaccine

3.6 Vaccination of close contacts of HSCT Recipients

The following live vaccines can be administered to siblings / close family contacts of HSCT recipients: MMR, VZV, Shingles and Rotavirus vaccines.

- MMR Vaccine should be given to contacts as per the national vaccination schedule.
- VZV vaccine (Varivax®) should be offered to healthy susceptible siblings (and adult family members who are VZV seronegative) of VZV seronegative patients. There is theoretical risk of transmitting the attenuated vaccine virus to a susceptible individual; as a precautionary measure, any person who develops a vesicular rash after receiving VZV vaccine should avoid direct contact with the patient until the rash is dry and crusted.
- Shingles vaccine (Zostavax®): Is offered to adults aged 70-79years old, so the patient's grandparents may be offered this vaccine. Rarely the transmission of vaccine virus may occur between those vaccinated who develop a varicella-like rash and susceptible contacts. As a

precautionary measure, any person who develops a vesicular rash after receiving Zostavax® should avoid direct contact with the patient until the rash is dry and crusted.

- Rotavirus vaccine (Rotarix®): Is given to infants aged 6-24 weeks. Rotarix should not be given to the patient but can be given to siblings. There is potential for transmission from the infant to immunocompromised contacts through the faecal-oral route for at least 14 days post-vaccination. However, vaccination will offer protection to household contacts from wild-type rotavirus disease and outweigh any risk from transmission of vaccine virus to any immunocompromised close contacts. Good personal hygiene should be observed following administration of Rotarix.

Appendices below are for circulation to GPs - to notify them of the vaccination schedule for each patient. Add your centre details.

References:

- Avanzini MA, Carra AM, Maccario R, et al (1995). Antibody response to pneumococcal vaccine in children receiving bone marrow transplantation. *J Clin Immunol*; 15: 137-144.
- Engelhard D, Cordonnier C, Shaw PJ, et al. Infectious disease working party of the European bone marrow transplantation (2002); Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplant survey. *Br J Haematol*. 2002; 117: 444-450.
- Feldman S, Lott L (1987). Varicella in children: impact of antiviral therapy and prophylaxis. *Pediatrics*; 80: 465-72.
- Green Book: Immunisation against infectious disease - 'The Green Book'. Public Health England. Last updated September 2014.
- Guinan EC, Molrine DC, Antin JH, et al (1994). Polysaccharide conjugate vaccine responses in bone marrow transplant patients. *Transplantation*; 57: 677-684.
- Hoyle C, Goldman (1994). Life-threatening infections occurring more than 3 months after BMT. 18 UK Bone Marrow Transplant Teams. *Bone Marrow Transplant*; 14: 247-252.
- Kaplan LJ, Daum RS, Smaron M, McCarthy CA (1992). Severe measles in immunocompromised patients. *JAMA*; 267: 1237-1241.
- Li Volti S, Mauro L, Di Gregorio F, et al (1994). Immune status and immune response to diphtheria-tetanus and polio vaccines in allogeneic bone marrow transplanted thalassemic patients. *Bone Marrow Transplant*; 14: 225-227.
- Ljungman P, Duraj V, Magnius L (1991). Response to immunisation against polio after allogeneic marrow transplantation. *Bone Marrow Transplant*; 7(2): 89-93.
- Ljungman P, Wiklund-Hammarsten M, Duraj V, et al (1990). Response to tetanus toxoid immunisation after allogeneic bone marrow transplantation. *J Infect Dis*; 162: 496-500.
- Machado CM, Cardoso MR, da Rocha IF, et al (2005). The benefit of influenza vaccination after bone marrow transplantation. *Bone Marrow Transplant*; 36: 897-900.
- Parkkali T, Stenvik M, Ruutu T, Hovi T, Volin L, Ruutu P (1997). Randomised comparison of early and late vaccination with inactivated poliovirus vaccine after allogeneic BMT. *Bone Marrow Transplant*; 20: 663-668.
- RCPCH: Immunisation of the immunocompromised child. February 2002.
- Schutze GE, Mason EO, Wald ER, et al (2001). Pneumococcal infections in children after transplantation. *Clin Infect Dis*; 33: 16-21.
- Sheridan JF, Tutschka PJ, Sedmak DD, Copelan EA (1990). Immunoglobulin G subclass deficiency and pneumococcal infection after allogeneic bone marrow transplantation. *Blood*; 75: 1583-1586.
- Winston DJ, Schiffman G, Wang D, et al (1979). Pneumococcal infections after human bone-marrow transplantation. *Annals of Internal Medicine*; 91: 835-841.
- Witherspoon RP, Storb R, Ochs HD, et al (1981). Recovery of antibody production in human allogeneic marrow graft recipients: influence of time post transplantation, the presence or absence of chronic graft-versus-host disease, and antithymocyte globulin treatment. *Blood*; 58: 360-368.

Appendix 1

INSERT CENTRE DETAILS

Vaccination schedule for patients beginning 6 months after completion of standard-dose chemotherapy

Patient name and DOB:

Date vaccinations will be due:

Time after EOT	Age under 10 years Vaccine	Age 10 years and over Vaccine
6 Months	DTaP / IPV ^{1,2} (Infanrix-IPV) Hib/Men C ^{1,2} (Menitorix) DTaP/IPV/Hib/HepB ² (Infanrix hexa) Men ACWY-conjugate (Menveo) PCV13 (Prevenar 13) Men B ³ (Bexsero) MMR ⁴ (Priorix or MMRVaxPRO)	dTaP / IPV ¹ (Repevax) Hib/Men C (Menitorix) Men ACWY-conjugate (Menveo) PCV13 (Prevenar 13) Men B ³ (Bexsero) MMR ⁴ (Priorix or MMRVaxPRO) HPV ⁵ (Gardasil)

[Vaccines: DTaP = Diphtheria/ Tetanus/ acellular Pertussis, dTaP = Low dose Diphtheria/ Tetanus/ acellular Pertussis, Hib = *H.influenzae b* conjugate, HepB =Hepatitis B, HPV = Human papillomavirus, IPV = Inactivated polio virus vaccine, Men B = Meningococcal B conjugate, Men C = Meningococcal C conjugate, Men ACWY = Meninococcal ACWY conjugate, MMR = Measles/Mumps/Rubella, PCV13 = 13 valent Pneumococcal conjugate, PnPS 23 = 23 valent pneumococcal polysaccharide]

¹ Can be given Infanrix-IPV (for <10 years age) or Repevax (for ≥10 years age)

² Give DTaP/IPV/Hib/HepB (Infanrix hexa) to children born after 1/07/17. Otherwise give DTaP / IPV (Infanrix-IPV) and Hib/Men C (Menitorix)

³ Give Men B vaccine to children born after 1/09/15

⁴ If patient did not receive MMR prior to starting chemotherapy give 2 doses MMR, if patient only received 1 dose of MMR prior to starting chemotherapy then should receive 2 doses of MMR after completion of chemotherapy. The 2nd dose should be given 6 months after the 1st dose. The 2nd dose can be given 3 months after the 1st dose or can be considered even earlier (1 month after 1st dose) in measles outbreak.

⁵ HPV vaccine should be offered to girls ≥12 years old: 2 doses of HPV vaccine (Gardasil) should be given at 0 and 6 months from starting re-vaccination. If patient is aged 15 years and over, 3 doses recommended at 0, 1, 6 months from starting re-vaccination. For girls that did complete the course, a booster dose should be given.

Subsequent routine booster doses will not be necessary if scheduled to be given within one year of the above booster doses.

BCG Vaccine: If patient has previously had BCG and is considered to be at high risk of tuberculosis, perform mantoux test and if negative, re-vaccinate. If patient has not previously had BCG vaccinate according to local policy.

Vaccination schedule for Bone marrow Transplant recipients**Patient name and DOB:****Date vaccinations will be due:**

Time after HSCT	Age under 10 years Vaccine	Age 10 years and over Vaccine
Every autumn (start 6 months after transplant)	Inactivated influenza ¹	Inactivated influenza ¹
12 Months	DTaP / IPV ^{2,3} (Infanrix-IPV) Hib / Men C ^{2,3} (Menitorix) DTaP/IPV/Hib/HepB ³ (Infanrix hexa) PCV13 Men B (Bexsero)	dTaP / IPV ² (Repevax) Hib / Men C ² (Menitorix) PCV13 Men B (Bexsero) HPV ⁴
13 Months	DTaP / IPV / Hib ^{2,3} (Pediacef) DTaP/IPV/Hib/HepB ³ (Infanrix hexa)	dTaP / IPV ² (Repevax) HPV ⁴
14 Months	DTaP / IPV ^{2,3} (Infanrix-IPV) Hib / Men C ^{2,3} DTaP/IPV/Hib/HepB ³ (Infanrix hexa) PCV13, Men B	dTaP / IPV ² (Repevax) Hib / Men C PCV13 Men B
18 Months	MMR ⁵	MMR ⁵ , HPV ⁴
24 Months	MMR ⁵ Men ACWY Men B PCV13 or PnPS23	MMR ⁵ Men ACWY Men B PCV13 or PnPS23
48 Months	DTaP / IPV (Infanrix-IPV) Hib / Men C	dTaP / IPV (Repevax) Hib / Men C
School leaver booster	dT / IPV (Revaxis) Men ACWY	dT / IPV (Revaxis) Men ACWY

[Vaccines: DTaP = Diphtheria/ Tetanus/ acellular Pertussis, dTaP = Low dose Diphtheria/ Tetanus/ acellular Pertussis, Hib = *H.influenzae b* conjugate, HepB =Hepatitis B, HPV = Human papillomavirus, IPV = Inactivated polio virus vaccine, Men B = Meningococcal B conjugate, Men C = Meningococcal C conjugate, Men ACWY = Meningococcal ACWY conjugate, MMR = Measles/Mumps/Rubella, PCV13 = 13 valent Pneumococcal conjugate, PnPS 23 = 23 valent pneumococcal polysaccharide]

¹The intranasal live-attenuated influenza vaccine should not be given to HSCT recipients. Note that the immune response to influenza vaccine is not optimal during the first 6 months after HSCT, which is the period of greatest risk; therefore vaccination should be offered to family members and hospital staff.

² Can be given as Infanrix-IPV (for <10 years age at administration) or Repevax (for ≥10 years age)

³ Give DTaP/IPV/Hib/HepB (Infanrix hexa) to children born after 1/07/17. Otherwise give DTaP / IPV (Infanrix-IPV) and Hib/Men C (Menitorix)

⁴ HPV vaccine should be offered to girls ≥12 years old: 2 doses of HPV vaccine (Gardasil) should be given at 0 and 6 months from starting re-vaccination. If patient is aged 15 years and over, 3 doses recommended at 0,1, 6 months from starting re-vaccination.

⁵ 1st dose of MMR should be given at 18 months provided patient is at least 12 months off all immunosuppressive treatment and fulfils criteria as above.